Apricus Biosciences, Inc.
Apricus Biosciences Announces Corporate Update, Fourth Quarter and Full Year 2015 Financial Results Conference Call
SAN DIEGO, 2016-03-02 13:00 CET (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that the Company's fourth quarter and full year 2015 financial results will be released on Wednesday, March 9, 2016 at 4:01 p.m. Eastern Time. Company management will host a conference call on Wednesday, March 9, 2016, at 5:00 p.m. Eastern Time to discuss the financial results and other recent corporate highlights.
To participate by telephone, please dial (855) 780-7196 (Domestic) or (631) 485-4867 (International). The conference ID number is 58434612. The live audio webcast can be accessed via the Investor Relations’ section of the Company's website atwww.apricusbio.com. Please log in approximately 5-10 minutes before the event to ensure a timely connection. The archived webcast will remain available for 30 days following the live call.
About Apricus Biosciences, Inc.
Apricus Biosciences, Inc. (APRI) is a biopharmaceutical company advancing innovative medicines in urology and rheumatology. Apricus recently completed enrollment in its Phase 2b trial for fispemifene, a selective estrogen receptor modulator for the treatment of symptomatic male secondary hypogonadism, and plans to conduct additional studies in other urological conditions. Apricus has completed a Phase 2a trial for RayVa™, its product candidate for the treatment of the circulatory disorder Raynaud’s phenomenon, and plans to conduct additional clinical trials in patients with Raynaud’s phenomenon secondary to scleroderma. Apricus’ lead commercial product, Vitaros®*, for the treatment of erectile dysfunction, is approved in Europe and Canada and is being commercialized in several countries in Europe. In September 2015, Apricus in-licensed the U.S. development and commercialization rights for Vitaros from Allergan. Apricus’ marketing partners for Vitaros include Laboratoires Majorelle, Bracco S.p.A., Hexal AG (Sandoz), Takeda Pharmaceuticals International GmbH, Recordati Ireland Ltd. (Recordati S.p.A.), Ferring International Center S.A. (Ferring Pharmaceuticals) and Mylan NV. Apricus’ second-generation room temperature Vitaros is currently under development.
For further information on Apricus, visithttp://www.apricusbio.com.
*Vitaros®is a registered trademark of NexMed International Limited. Such trademark is registered in certain countries throughout the world and pending registration in the United States.
CONTACT: Institutional / Retail Investors: Matthew Beck
The Trout Group LLC
Information om Nasdaq OMX
Følg pressemeddelelser fra Nasdaq OMX
Skrive dig op her og du vil løbende modtage pressemeddelelser på mail. Indtast din mail, klik på abonner og følg instruktionerne i den udsendte mail.
Flere pressemeddelelser fra Nasdaq OMX
Taconic Biosciences21.2.2018 19:15 | pressemeddelelse
Taconic Biosciences Announces the Formation of Scientific Advisory Board
TrueCommerce21.2.2018 16:01 | pressemeddelelse
TrueCommerce Dynamics 365 Solution Featured on Microsoft AppSource
Cisco21.2.2018 14:01 | pressemeddelelse
Cisco 2018 Annual Cybersecurity Report Reveals Security Leaders Rely on and Invest in Automation, Machine Learning and Artificial Intelligence to Defend Against Threats
Appian Corporation21.2.2018 13:31 | pressemeddelelse
Appian Corporation : Banco Santander Selects Appian
Inspiration Mining Corporation20.2.2018 21:37 | pressemeddelelse
Inspiration Mining to File a Complaint with OSC Against Stockwatch
Aurora Solar Technologies Inc.20.2.2018 21:09 | pressemeddelelse
Aurora Releases Third Quarter Results
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter, og finde vores kontaktoplysninger.Besøg vores nyhedsrum